Oncology
Soligenix's HyBryte™ Demonstrates Promising Results in Rare Skin Cancer Treatment
A novel skin cancer therapy shows a 75% response rate in treating cutaneous T-cell lymphoma, offering potential hope for patients with limited treatment options. The treatment's safety profile and rapid results could significantly impact rare cancer care.
Kairos Pharma Secures Department of Defense Grant for Lung Cancer Biomarker Research
Kairos Pharma has received a Department of Defense grant to advance research on lung cancer biomarkers, furthering its innovative approach to targeting drug resistance in cancer treatments. The company is progressing clinical trials for its lead candidates ENV105 and KROS101 with promising potential in oncology.
Ohio State Researchers Uncover Potential Breakthrough in Glioblastoma Treatment
Scientists have identified a key enzyme, PGM3, that could be crucial in developing more effective treatments for glioblastoma, one of the deadliest forms of brain cancer by targeting a critical growth pathway.
Calidi Biotherapeutics Receives FDA Clearance for Innovative Cancer Treatment Trial
Biotech firm Calidi Biotherapeutics has obtained FDA approval to begin clinical trials of CLD-201, a novel stem cell-based virotherapy targeting solid tumors. The therapeutic approach combines adipose-derived stem cells with oncolytic vaccinia virus, potentially offering a breakthrough in treating challenging cancer types.
DoD Awards $876,000 Grant to Advance Lung Cancer Biomarker Research at Cedars-Sinai
The U.S. Department of Defense has provided funding to Cedars-Sinai Medical Center to support biomarker research for Kairos Pharma's experimental lung cancer treatment, focusing on identifying potential early intervention strategies for patients developing resistance to current therapies.
Global Brain Tumor Treatment Market Projected to Reach $7.15 Billion by 2035
The brain tumor treatment market is expected to experience substantial growth, driven by advances in medical technologies like immunotherapy and personalized medicine. The market's projected 7.2% compound annual growth rate signals significant potential for medical innovation and investment.
Silexion's Cancer Drug Shows Promise in Precision Oncology Market
Silexion Therapeutics demonstrates significant progress in KRAS-targeted cancer treatment with their RNAi therapeutic SIL-204, positioning the company as a notable player in the rapidly consolidating precision oncology market valued in billions.